Efficacy of shakubaqu valsartan in patients with heart failure with preserved ejection fraction after emergency PCI for AMI and the effect on major cardiovascular events

Tao Chengmin; Xie Wei; Xu Xiaodong

doi:10.3969/j.issn.1674-4055.2024.03.15

Abstract：Objective To explore the efficacy and impact on major cardiovascular events(MACE)of shakubaqu valsartan in patients with combined heart failure with preserved ejection fraction(HFpEF)after acute myocardial infarction(AMI)emergency percutaneous coronary intervention(PCI).Methods Sixty patients with combined HFpEF after emergency PCI for AMI admitted to our hospital from January 2021 to January 2023 were selected for the study.They were divided into observation and control groups using the random number table method,with 30 cases in each group.In the control group,valsartan was applied based on conventional treatment,while in the observation group,shakubaqu valsartan was applied based on conventional.The 6 min walking distance(6MWD),echocardiographic indices[left ventricular ejection fraction(LVEF),left ventricular end-diastolic internal diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular posterior wall thickness(LVPWT),left atrial internal diameter(LAD)and peak flow velocity ratio(E/A value)],heart rate,diastolic blood pressure,systolic blood pressure,and N-terminal pro-brain natriuretic peptide(NT-proBNP)level were compared between the two groups before and after treatment.The clinical efficacy and the occurrence of MACE were observed in the two groups.Results The total effective rate of treatment in the observation group(93.33%)was higher than that in the control group(73.33%),(P<0.05).6MWD increased in both groups after treatment,and 6MWD in the observation group was higher than in the control group(P<0.05).NT-proBNP decreased in both groups after treatment compared with that before treatment,and NT-proBNP in the observation group was lower than in the control group(P<0.05).There were no statistical differences in LVEDD,LVESD,LVPWT and LAD indexes between the two groups before and after treatment(P>0.05).LVEF and E/A ratios were higher in the two groups after treatment than before,and the E/A ratio was higher in the observation group than in the control group(P<0.05).There was no statistical difference in LVEF between the two groups after treatment(P>0.05).After treatment,the two group's heart rate,systolic blood pressure,and diastolic blood pressure were lower than before treatment(P<0.05).However,there was no statistically significant difference between the two groups after treatment(P>0.05).The incidence of MACE in the observation group(3.33%)was lower than that in the control group(26.67%),(P<0.05).Conclusion The efficacy of shakubaqu valsartan in treating patients with combined HFpEF after AMI emergency PCI is significant,improving activity tolerance and cardiac function,reducing heart rate,blood pressure,and NT-proBNP level,improving LVEF and ventricular diastolic function,and reducing the incidence of MACE.